Highlights of This Issue 1

**SMALL MOLECULE THERAPEUTICS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor</td>
<td>Andrew R. Larsen, Ren-Yuan Bai, Jon H. Chung, Alexandra Borodovsky, Charles M. Rudin, Gregory J. Riggins, and Fred Bunz</td>
</tr>
<tr>
<td>14</td>
<td>TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</td>
<td>Shuichi Ohkubo, Yasuo Kodama, Hiromi Muraoka, Hirotoki Hiyoshi, Chihoko Yoshimura, Makoto Kitade, Akira Gomori, Koichi Takahashi, Yoshiohito Shibata, Akira Kanoh, and Kazushiho Yonekura</td>
</tr>
<tr>
<td>23</td>
<td>Darinaparsin Inhibits Prostate Tumor–Initiating Cells and Du145 Xenografts and Is an Inhibitor of Hedgehog Signaling</td>
<td>Nitu Bansal, Nadine Johnson Farley, Lisa Wu, Jonathan Lewis, Hagop Youssoufian, and Joseph R. Bertino</td>
</tr>
<tr>
<td>31</td>
<td>Preclinical Characterization of RSM-932A, a Novel Anticancer Drug Targeting the Human Choline Kinase Alpha, an Enzyme Involved in Increased Lipid Metabolism of Cancer Cells</td>
<td>Juan Carlos Lacal and Joaquín M. Campos</td>
</tr>
<tr>
<td>40</td>
<td>Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer</td>
<td>Melissa J. Jantrue, Vidusha Devasthali, Jason H. Cheng, Joseph Castillo, Ciara Metcalfe, Anne C. Clermont, Douglas Den Otter, Emily Chan, Hani Bou-Reslan, Tim Cao, William Forrest, Michelle A. Nannini, Dorothy French, Richard Carano, Mark Merchant, Klaus P. Hoeflich, and Mallika Singh</td>
</tr>
<tr>
<td>48</td>
<td>Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel</td>
<td>Urs Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan, Rebecca Elston, Hannah Dry, Claire Crafer, Bernard Barlham, Martina Fitzek, Paul D. Smith, Donald Ogilvie, Celina D’Cruz, Lillian Castriotta, Stephen R. Wedge, Lara Ward, Steve Powell, Mandy Lawson, Barry R. Davies, Elizabeth A. Harrington, Emily Foster, Marie Cumberbatch, Stephen Green, and Simon T. Barry</td>
</tr>
<tr>
<td>59</td>
<td>Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer</td>
<td>Paul J. Toren, Soojin Kim, Steven Pham, Azza Mangalji, Hans Adomat, Emma S. Tomlinson Gums, Amina Zoubi, William Moore, and Martin E. Gleave</td>
</tr>
<tr>
<td>80</td>
<td>Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma</td>
<td>Xianguan Zhao, William M. Puszyk, Zaiming Lu, David A. Ostrov, Thomas J. George, Keith D. Robertson, and Chen Liu</td>
</tr>
<tr>
<td>90</td>
<td>The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity</td>
<td>Ki-Eun Chang, Bi-Rong Wei, James P. Madigan, Matthew D. Hall, R. Mark Simpson, Zhengqing Zhuang, and Michael M. Gottesman</td>
</tr>
<tr>
<td>101</td>
<td>Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models</td>
<td>Eric Ciamporcero, Kiersten Marie Miles, Remi Adelaiye, Swathi Ramakrishnan, Li Shen, ShengYu Ku, Stefania Pizzimenti, Barbara Sennino, Giuseppina Barbera, and Roberto Pili</td>
</tr>
</tbody>
</table>
Table of Contents

120  Tumor-Penetrating iRGD Peptide Inhibits Metastasis
    Kazuki N. Sugahara, Gary B. Braun, Tatiana Hurtado de Mendoza, Venkata Ramana Kotamraju, Randall P. French, Andrew M. Lowy, Tambet Teesalu, and Erkki Ruoslahti

LARGE MOLECULE THERAPEUTICS

129  ANG4043, a Novel Brain-Penetrant Peptide-mAb Conjugate, Is Efficacious against HER2- Positive Intracranial Tumors in Mice
    Anthony Regina, Michel Demeule, Sasmita Tripathy, Simon Lord-Dufour, Jean-Christophe Currie, Mustapha Ildir, Borhane Annabi, Jean-Paul Castaigne, and Jean E. Lachowicz

141  Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer
    Kazuhide Sato, Hirofumi Hanaoka, Rira Watanabe, Takahito Nakajima, Peter L. Choyke, and Hisataka Kobayashi

151  Bicyclic Peptides Conjugated to an Albumin-Binding Tag Diffuse Efficiently into Solid Tumors
    Lisa Pollaro, Sandeep Raghunathan, Julia Morales-Sanfrutos, Alessandro Angelini, Stephan Kontos, and Christian Heinis

162  Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody
    Zheng Zhang, Yang Zhang, Qian Sun, Fei Feng, Muren Huhe, Li Mi, and Zhinan Chen

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

174  Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
    Yang Liu and David J. Kwiatkowski

183  SRT1720 Induces Lyososomal-Dependent Cell Death of Breast Cancer Cells
    Tyler J. Lahusen and Chu-Xia Deng

193  Mechanisms of Resistance to Cabazitaxel
    George E. Duran, Yan C. Wang, E. Brian Francisco, John C. Rose, Francisco J. Martinez, John Collet, Diana Brassard, Patricia Vrignaud, and Branimir I. Sikic

202  Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors
    Elspeth M. Beauchamp, Ewa M. Kosciuczuk, Ruth Serrano, Dhaval Nanavati, Elden P. Swindell, Benoit Viollet, Thomas V. O’Halloran, Jessica K. Altman, and Leonidas C. Platanias

213  Midkine Lacking Its Last 40 Amino Acids Acts on Endothelial and Neuroblastoma Tumor Cells and Inhibits Tumor Development
    Noushin Dianat, Barbara Le Viet, Emilie Gobbo, Nathalie Auger, Ivan Börje, Amelina Remacce-Griscelli, and Frank Griscelli

225  ANP63a Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis
    Andrew J. DeCastro, Pratima Cherukuri, Amanda Balboni, and James DiRienzo

236  Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?
    Vijaya L. Damaraju, Michelle Kuzma, Delores Mowles, Carol E. Cass, and Michael B. Sawyer

246  Elevated IJN Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation
    Katerina Mardilovich, Mads Gabrielsen, Lynn McGarry, Clare Orange, Rachana Patel, Emma Shanks, Joanne Edwards, and Michael F. Olson

259  Enhanced Colonic Tumorigenesis in Alkaline Sphingomyelinase (NPP7) Knockout Mice
    Ying Chen, Ping Zhang, Shu-Chang Xu, Leping Yang, Ulrikke Voss, Eva Ekblad, Yunjin Wu, Yalan Min, Erik Hertervig, Åke Nilsson, and Rui-Dong Duan

268  Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
    Feng-qi Nie, Ming Sun, Jin-song Yang, Min Xie, Tong-peng Xu, Rui Xia, Yan-wen Liu, Xiang-yun Liu, Er-bao Zhang, Kai-hua Lu, and Yong-qian Shu
Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling

The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Yufeng Hu, Hexiu Su, Xu Li, Guoli Guo, Ling Cheng, Renyi Qin, Guoliang Qing, and Hudan Liu

Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Lauren S. Fink, Alexander Beatty, Karthik Devarajan, Suraj Peri, and Jeffrey R. Peterson

Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies
Walter Hans Meisen, Samuel Dubin, Steven T. Sizemore, Haritha Mathsyaraja, Katie Thies, Norman L. Lehman, Peter Boyer, Alena Cristina Jaime-Ramirez, J. Bradley Elder, Kimberly Powell, Amal Chakravarti, Michael C. Ostrowski, and Balveen Kaur

ABOUT THE COVER
Tumor antigen–targeting mAbs, such as Herceptin, are critical weapons in the cancer therapeutic arsenal, yet they cross the blood–brain barrier (BBB) poorly and their success treating brain tumors is limited. By conjugating an anti-HER2 mAb with a peptide that utilizes receptor-mediated transcytosis across the BBB, a brain-penetrant mAb, ANG4043, was created. ANG4043’s retention of tumor-targeting properties was demonstrated in HER2-positive BT-474 breast carcinoma cells. Colocalization of the control anti-HER2 mAb and the HER2 antigen is shown in yellow on the cell surface. For details, see article by Regina and colleagues on page 129.